Cargando…
Dasatinib‐induced hypoglycemia in a patient with acute lymphoblastic leukemia
Tyrosine kinase inhibitors can cause significant hypoglycemia in patients with diabetes on other antihyperglycemic medications. These patients should be monitored, and their medications adjusted accordingly.
Autores principales: | Lundholm, Michelle D., Charnogursky, Gerald A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7364065/ https://www.ncbi.nlm.nih.gov/pubmed/32695366 http://dx.doi.org/10.1002/ccr3.2901 |
Ejemplares similares
-
Hypoglycemia associated with L-asparaginase in acute lymphoblastic leukemia treatment: a case report
por: Tanaka, Ryuma, et al.
Publicado: (2012) -
Allopurinol reverses mercaptopurine-induced hypoglycemia in patients with acute lymphoblastic leukemia
por: Zhang, Melissa, et al.
Publicado: (2019) -
Dasatinib in the Management of Pediatric Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
por: Cerchione, Claudio, et al.
Publicado: (2021) -
Recurrent Gastrointestinal Hemorrhage in Children with Philadelphia-Positive B-Cell Acute Lymphoblastic Leukemia Treated with Dasatinib: Case Reports
por: Liao, Xin, et al.
Publicado: (2020) -
Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia
por: Fei, Fei, et al.
Publicado: (2010)